BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31311652)

  • 21. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Delaloge S; Khan SA; Wesseling J; Whelan T
    Lancet; 2024 Jun; 403(10445):2734-2746. PubMed ID: 38735296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ductal carcinoma in situ: treatment or active surveillance?
    Kuerer HM
    Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ductal carcinoma in situ (DCIS). A highly treatable breast cancer.
    Mayo Clin Womens Healthsource; 2009 Oct; 13(10):1-2. PubMed ID: 19727033
    [No Abstract]   [Full Text] [Related]  

  • 25. Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ.
    Levinsohn E; Altman M; Chagpar AB
    Am Surg; 2018 Jan; 84(1):1-6. PubMed ID: 29428007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ductal Carcinoma In Situ: Treatment Update and Current Trends.
    Mitchell KB; Kuerer H
    Curr Oncol Rep; 2015 Nov; 17(11):48. PubMed ID: 26373411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.
    Elshof LE; Schmidt MK; Rutgers EJT; van Leeuwen FE; Wesseling J; Schaapveld M
    Ann Surg; 2018 May; 267(5):952-958. PubMed ID: 28375855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS).
    Cheung S; Booth ME; Kearins O; Dodwell D
    Breast; 2014 Dec; 23(6):807-11. PubMed ID: 25270228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Call for Change in the Diagnosis and Treatment of Patients with Ductal Carcinoma In Situ: An Opportunity to Minimize Overdiagnosis and Overtreatment.
    Masood S
    Breast J; 2015; 21(6):575-8. PubMed ID: 26547899
    [No Abstract]   [Full Text] [Related]  

  • 30. A Biological Signature for Breast Ductal Carcinoma
    Bremer T; Whitworth PW; Patel R; Savala J; Barry T; Lyle S; Leesman G; Linke SP; Jirström K; Zhou W; Amini RM; Wärnberg F
    Clin Cancer Res; 2018 Dec; 24(23):5895-5901. PubMed ID: 30054280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current perspectives of treatment of ductal carcinoma in situ.
    Estévez LG; Alvarez I; Seguí MÁ; Muñoz M; Margelí M; Miró C; Rubio C; Lluch A; Tusquets I
    Cancer Treat Rev; 2010 Nov; 36(7):507-17. PubMed ID: 20462701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
    Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is DCIS Overrated?
    Feinberg J; Wetstone R; Greenstein D; Borgen P
    Cancer Treat Res; 2018; 173():53-72. PubMed ID: 29349758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions.
    Ryan R; Tawfik O; Jensen RA; Anant S
    Prog Mol Biol Transl Sci; 2017; 151():33-80. PubMed ID: 29096897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast.
    Boughey JC; Gonzalez RJ; Bonner E; Kuerer HM
    Oncologist; 2007 Nov; 12(11):1276-87. PubMed ID: 18055847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Ductal Carcinoma In Situ: Advances and Future Perspectives.
    Behbod F; Chen JH; Thompson A
    Cold Spring Harb Perspect Med; 2023 Oct; 13(10):. PubMed ID: 36781223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ductal carcinoma in situ of the breast: can biomarkers improve current management?
    Bartlett JM; Nofech-Moses S; Rakovitch E
    Clin Chem; 2014 Jan; 60(1):60-7. PubMed ID: 24262106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?
    Punglia RS; Schnitt SJ; Weeks JC
    J Natl Cancer Inst; 2013 Oct; 105(20):1527-33. PubMed ID: 24068769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
    Théberge I; Vandal N; Guertin MH; Perron L
    Breast Cancer Res Treat; 2019 Apr; 174(2):525-535. PubMed ID: 30564969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of ductal carcinoma in situ in the modern era.
    Khan A; Dumitru D; Catanuto G; Rocco N; Nava MB; Benson J
    Minerva Chir; 2018 Jun; 73(3):303-313. PubMed ID: 29589680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.